<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5344">
  <stage>Registered</stage>
  <submitdate>25/03/2015</submitdate>
  <approvaldate>25/03/2015</approvaldate>
  <nctid>NCT02412735</nctid>
  <trial_identification>
    <studytitle>A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain</studytitle>
    <scientifictitle>A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain</scientifictitle>
    <utrn />
    <trialacronym>MSB-DR003</trialacronym>
    <secondaryid>MSB-DR003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Degenerative Disc Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - rexlemestrocel-L
Treatment: drugs - rexlemestrocel-L + HA
Treatment: drugs - Placebo

Experimental: rexlemestrocel-L - rexlemestrocel-L alone": 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells

Experimental: rexlemestrocel-L + HA - rexlemestrocel-L + HA": 2.0mL 6 million rexlemestrocel-L cells

Placebo Comparator: Placebo - saline control: 2.0 mL saline solution


Treatment: drugs: rexlemestrocel-L
rexlemestrocel-L alone": 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells - Intervention will be injected into the painful intervertebral disc

Treatment: drugs: rexlemestrocel-L + HA
rexlemestrocel-L + HA": 2.0mL 6 million rexlemestrocel-L cells with 1% HA - Intervention will be injected into the painful intervertebral disc

Treatment: drugs: Placebo
saline control: 2.0 mL saline solution

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment Success (composite responder analysis of low back pain Visual Analogue Scale (VAS) score, Oswestry Disability Index (ODI) score and no post-treatment interventions) -  To determine Overall Treatment Success of rexlemestrocel-L alone or rexlemestrocel-L+HA through 24 months based on a composite responder analysis</outcome>
      <timepoint>24 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effectiveness (Pain Responder analysis) -  To evaluate the effectiveness of rexlemestrocel-L alone or rexlemestrocel-L+HA in reducing chronic low back pain by performing a Pain Responder analysis through 24 months post-treatment</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effectiveness (Functional Responder analysis) -  To evaluate the effectiveness of rexlemestrocel-L alone or rexlemestrocel-L+HA in improving function by performing a Functional Responder analysis through 24 months post-treatment</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effectiveness (Treatment Success at 24 months) - To determine the Treatment Success at 24 months of rexlemestrocel-L alone or rexlemestrocel-L+HA based upon a composite responder analysis</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effectiveness (Minimal Pain Responder at 24 months) - Minimal Pain Responder at 24 Months: Measured as subjects meeting low back pain VAS score threshold</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effectiveness (Time to first intervention) - To evaluate the effectiveness of rexlemestrocel-L alone or rexlemestrocel-L+HA on reducing the time to additional interventions at the treated level over 24 months post-treatment.</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male and female subjects 18 years of age and older

          -  If female of childbearing potential, subject is non-pregnant, non-nursing, and agrees
             to use highly effective methods of contraception for a minimum of 24 months
             post-treatment

          -  Signed informed consent and country-appropriate privacy forms indicating subject is
             willing to undergo treatment and willing to be available for each examination
             scheduled over the study duration

          -  Have documented diagnosis of moderate radiographic degeneration of an intervertebral
             disc from L1 to S1, with a disc suspected of causing CLBP Chronic low back pain
             associated with moderate radiographic degeneration at a lumbar disc is defined as the
             following (subject must meet all of the listed conditions):

               1. Chronic low back pain for at least 6 months

               2. Have failed 6 months of conservative back pain care. (Conservative treatment
                  regimens may include any or all of the following: initial rest, medications
                  [e.g., anti-inflammatory, analgesics, narcotics/opioids, muscle relaxants],
                  massage, acupuncture, chiropractic manipulations, activity modification,
                  home-directed lumbar exercise program, and non-invasive pain control treatments
                  or procedures)

               3. Have at a minimum undergone supervised physical therapy, such as daily walking
                  routines, therapeutic exercises, and back education programs specifically for the
                  treatment of low back pain AND taken a pain medication for back pain (e.g. NSAID
                  and/or opioid medication).

               4. Change from normal disc morphology of the index disc as defined by radiographic
                  evaluation by the core imaging evaluation provider. Radiographs must show all of
                  the following:

          -  A modified Pfirrmann score of 3, 4, 5 or 6 on MRI at the index disc

          -  Modic Grade II changes or less on MRI at the index disc

          -  With or without contained disc protrusion at the index disc on MRI

             e. Low back pain of at least 40mm and not more than 90mm of 100mm on low back pain VAS
             (average pain over 24 hours)

             f. Leg pain =20mm in both legs on a 100mm VAS scale

             g. ODI score of at least 30 and no more than 90 on a 100 point scale.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Female subjects who are pregnant or nursing, or women planning to become pregnant in
             the first 24 months post-treatment

          -  Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI &gt; 40)

          -  Have undergone a surgical procedure (e.g. discectomy, intradiscal electrothermal
             therapy, intradiscal radiofrequency, artificial disc replacement, interbody fusion) on
             the disc at the index or adjacent level

          -  Osteoporosis, as defined by dual-energy X-ray absorptiometry (DEXA) scan. A DEXA
             T-score of = -2.5 will exclude the subject.

          -  Any lumbar intradiscal injection, including steroids, into the index or adjacent discs
             prior to treatment injection, with the exception of the following injections performed
             at least 2 weeks prior to study treatment:

               1. Contrast medium (discography or other diagnostic injection)

               2. NSAIDs

               3. Nerve-blocking anesthetics (e.g., lidocaine, bupivacaine)

               4. Antibiotics

               5. Saline

          -  Have undergone a procedure affecting the structure/biomechanics of the index disc
             level (e.g., posterolateral fusion)

          -  Active malignancy or tumor as source of symptoms or history of malignancy within the 5
             years prior to enrolment on study

          -  Have been a recipient of prior allogeneic stem cell/progenitor cell therapy for any
             indication or autologous stem cell/progenitor cell therapy or other biological
             intervention to repair the index intervertebral disc

          -  An average baseline morphine equivalent dose (MED) of &gt;75mg/day as determined by
             e-diary entries during the screening period

          -  Taking systemic immunosuppresants

          -  A medical condition, serious intercurrent illness, or extenuating circumstance that
             would preclude participation in the study or potentially decrease survival or
             interfere with ambulation or rehabilitation.

          -  Subjects involved in spinal litigation, including workman's compensation, unless
             litigation is complete

          -  Are transient or has a severe alcohol or substance abuse problem

          -  Clinically significant nerve pain (e.g., chronic radiculopathy or neuropathy)

          -  Clinically significant sacroiliac joint pain

          -  Compressive pathology due to stenosis or disc protrusion on MRI with associated
             clinical symptoms defined as leg pain VAS&gt;20mm out of 100mm or neurologic deficit on
             neurologic exam

          -  Disc extrusion or sequestration in the lumbar spine on MRI as determined by
             radiographic core lab

          -  Modified Pfirrmann score of 7 or 8 at any lumbar level (L1-S1) on MRI evaluation as
             determined by radiographic core lab

          -  Symptomatic involvement of more than one lumbar disc

          -  Symptomatic central vertebral canal stenosis as defined by neurogenic claudication

          -  Spondylolisthesis or retrolisthesis Grade 2 and above or Spondylolysis at the index or
             adjacent level(s)

          -  Lumbar spondylitis or other undifferentiated spondyloarthropathy affecting the index
             disc

          -  Spinal deformity defined as lumbar scoliosis with a Cobb angle of the lumbar spine
             greater than 15 degrees

          -  Any fracture of the spine at the index or adjacent levels that has not healed, or
             clinically compromised vertebral bodies at the index level due to current or past
             trauma

          -  Facet pain at the index level or adjacent segments as determined by a diagnostic
             medial branch block to rule out facet joint involvement.

          -  Full thickness annular tears in the index level as determined by free flowing contrast
             media through the annulus fibrosis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>360</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Medical Center - Clayton</hospital>
    <postcode>3168 - Clayton</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mesoblast, Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Quintiles, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3
      study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or
      combined with hyaluronic acid (HA) in subjects with chronic low back pain (&gt; 6 months)
      associated with moderate radiographic degenerative changes of a disc</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02412735</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Roger Brown</name>
      <address>Mesoblast, Ltd.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>David Nunez</name>
      <address />
      <phone>512-826-8897</phone>
      <fax />
      <email>david.nunez@mesoblast.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>